WO2003020931A3 - Sirna knockout assay method and constructs - Google Patents

Sirna knockout assay method and constructs Download PDF

Info

Publication number
WO2003020931A3
WO2003020931A3 PCT/EP2002/009670 EP0209670W WO03020931A3 WO 2003020931 A3 WO2003020931 A3 WO 2003020931A3 EP 0209670 W EP0209670 W EP 0209670W WO 03020931 A3 WO03020931 A3 WO 03020931A3
Authority
WO
WIPO (PCT)
Prior art keywords
constructs
assay method
sirna knockout
methods
knockout assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/009670
Other languages
French (fr)
Other versions
WO2003020931A2 (en
Inventor
Gert-Jan Arts
Ellen Vera Langemeijer
Ivo Piest
Es Helmuth Hendrikus Gerar Van
Godefridus Augustinus Michiels
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos Genomics NV
Original Assignee
Galapagos Genomics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26980845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003020931(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galapagos Genomics NV filed Critical Galapagos Genomics NV
Priority to AU2002339458A priority Critical patent/AU2002339458A1/en
Priority to DE60225586.4T priority patent/DE60225586T3/en
Priority to CA002457419A priority patent/CA2457419A1/en
Priority to EP02776950.4A priority patent/EP1444346B2/en
Priority to JP2003525634A priority patent/JP2005501557A/en
Publication of WO2003020931A2 publication Critical patent/WO2003020931A2/en
Publication of WO2003020931A3 publication Critical patent/WO2003020931A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to polynucleotide constructs, methods for their preparation, and preparations for their use in methods that lower the amount of RNA and/or protein production in cells based on the intracellular expression of small interfering polyribonucleic acid molecules.
PCT/EP2002/009670 2001-09-01 2002-08-29 Sirna knockout assay method and constructs Ceased WO2003020931A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002339458A AU2002339458A1 (en) 2001-09-01 2002-08-29 Sirna knockout assay method and constructs
DE60225586.4T DE60225586T3 (en) 2001-09-01 2002-08-29 SIRNA KNOCKOUT TEST PROCEDURE AND CONSTRUCTS
CA002457419A CA2457419A1 (en) 2001-09-01 2002-08-29 Sirna knockout assay method and constructs
EP02776950.4A EP1444346B2 (en) 2001-09-01 2002-08-29 Sirna knockout assay method and constructs
JP2003525634A JP2005501557A (en) 2001-09-01 2002-08-29 siRNA knockout assays and constructs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31722901P 2001-09-01 2001-09-01
US60/317,229 2001-09-01
US38573302P 2002-06-04 2002-06-04
US60/385,733 2002-06-04

Publications (2)

Publication Number Publication Date
WO2003020931A2 WO2003020931A2 (en) 2003-03-13
WO2003020931A3 true WO2003020931A3 (en) 2003-11-20

Family

ID=26980845

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/009670 Ceased WO2003020931A2 (en) 2001-09-01 2002-08-29 Sirna knockout assay method and constructs

Country Status (8)

Country Link
US (2) US20030198627A1 (en)
EP (1) EP1444346B2 (en)
JP (1) JP2005501557A (en)
AT (1) ATE389016T2 (en)
AU (1) AU2002339458A1 (en)
CA (1) CA2457419A1 (en)
DE (1) DE60225586T3 (en)
WO (1) WO2003020931A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946177B2 (en) 2004-11-12 2015-02-03 Mima Therapeutics, Inc Methods and compositions involving miRNA and miRNA inhibitor molecules

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956568A1 (en) 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
GB9925459D0 (en) 1999-10-27 1999-12-29 Plant Bioscience Ltd Gene silencing
DE10100586C1 (en) * 2001-01-09 2002-04-11 Ribopharma Ag Inhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
US20030084471A1 (en) * 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
US8202846B2 (en) 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
US7767802B2 (en) * 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7423142B2 (en) * 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
IL159756A0 (en) 2001-07-12 2004-06-20 Univ Massachusetts IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
EP1281767A3 (en) 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
DE10163098B4 (en) * 2001-10-12 2005-06-02 Alnylam Europe Ag Method for inhibiting the replication of viruses
US20040121348A1 (en) * 2001-10-26 2004-06-24 Ribopharma Ag Compositions and methods for treating pancreatic cancer
DE10230997A1 (en) * 2001-10-26 2003-07-17 Ribopharma Ag Drug to increase the effectiveness of a receptor-mediates apoptosis in drug that triggers tumor cells
CA2468955A1 (en) * 2001-11-28 2003-06-05 Toudai Tlo, Ltd. Sirna expression system and process for producing functional gene knockdown cell or the like using the same
GB0130955D0 (en) * 2001-12-24 2002-02-13 Cancer Res Ventures Expression system
DE10202419A1 (en) 2002-01-22 2003-08-07 Ribopharma Ag Method of inhibiting expression of a target gene resulting from chromosome aberration
US7820632B2 (en) 2002-02-14 2010-10-26 City Of Hope Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules
US8137910B2 (en) 2002-05-03 2012-03-20 Duke University Method of regulating gene expression
WO2003095652A2 (en) * 2002-05-08 2003-11-20 Xantos Biomedicine Ag Expression constructs for producing double-stranded (ds) rna and the use thereof
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
EP1369491A1 (en) 2002-06-05 2003-12-10 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
EP1546408A4 (en) * 2002-09-20 2007-10-10 Pharmacia & Upjohn Co Llc A METHOD FOR GENERATION OF A RANDOM RNAi LIBRARY AND ITS APPLICATION IN CELL-BASED SCREENS
US7892793B2 (en) 2002-11-04 2011-02-22 University Of Massachusetts Allele-specific RNA interference
EP1592412A1 (en) * 2003-01-31 2005-11-09 Novartis AG Down-regulation of target-gene with pei/single-stranded oligoribonucleotide complexes
WO2004094636A1 (en) * 2003-04-24 2004-11-04 Galapagos Genomics N.V. Effective sirna knock-down constructs
CA2523785A1 (en) * 2003-05-09 2004-11-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Small interfering rna libraries and methods of synthesis and use
US7750144B2 (en) 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
EP1633890B2 (en) 2003-06-02 2020-11-18 University of Massachusetts METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF FNAi
PT1633767T (en) 2003-06-02 2019-02-27 Univ Massachusetts Methods and compositions for controlling efficacy of rna silencing
ATE420160T1 (en) 2003-06-18 2009-01-15 Genelux Corp MODIFIED RECOMBINANT VACCINIA VIRUSES, USES THEREOF
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
US20060134787A1 (en) 2004-12-22 2006-06-22 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
WO2005063983A1 (en) * 2003-12-29 2005-07-14 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
ES2425749T3 (en) 2004-03-31 2013-10-17 The General Hospital Corporation Method for determining the response of cancer to treatments directed at the epidermal growth factor receptor
EP2270513A3 (en) 2004-04-20 2011-04-06 Galapagos N.V. Methods, compositions and compound assays for inhibiting amyloid-beta protein production
WO2005103716A2 (en) 2004-04-27 2005-11-03 Galapagos N.V. Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
EP2290073A3 (en) 2004-05-28 2011-08-31 Asuragen, Inc. Methods and compositions involving microRNA
WO2005121778A2 (en) 2004-06-14 2005-12-22 Galapagos N.V. Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases
JP2008503712A (en) 2004-06-21 2008-02-07 ガラパゴス・ナムローゼ・フェンノートシャップ Methods and means for treatment of osteoarthritis
JPWO2006006520A1 (en) * 2004-07-09 2008-04-24 株式会社ジェノファンクション New drug discovery method
US8673268B2 (en) 2004-10-15 2014-03-18 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
CA2609142C (en) 2005-05-27 2016-02-09 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic gene vectors comprising mirna target sequences
US7919583B2 (en) 2005-08-08 2011-04-05 Discovery Genomics, Inc. Integration-site directed vector systems
EP1937066A4 (en) 2005-08-18 2008-12-24 Alnylam Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
AU2014202015B2 (en) * 2006-03-07 2016-06-02 The Trustees Of The University Of Pennsylvania Random RNAi libraries, methods of generating same, and screening methods utilizing same
JP5463039B2 (en) * 2006-03-07 2014-04-09 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Random RNAi library, method for generating the same, and screening method using the same
FR2898908A1 (en) 2006-03-24 2007-09-28 Agronomique Inst Nat Rech PROCESS FOR PREPARING DIFFERENTIATED AVIAN CELLS AND GENES INVOLVED IN MAINTAINING PLURIPOTENCE
WO2007137220A2 (en) * 2006-05-22 2007-11-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of ikk-b gene
WO2007147067A2 (en) * 2006-06-14 2007-12-21 Rosetta Inpharmatics Llc Methods and compositions for regulating cell cycle progression
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
JP2008086201A (en) * 2006-09-29 2008-04-17 Gifu Prefecture Kenkyu Kaihatsu Zaidan MicroRNA production detection method, cancer diagnosis / treatment and microRNA production regulator
EP2097517B1 (en) 2006-10-16 2014-06-04 Genelux Corporation Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody
US8114982B2 (en) * 2006-12-06 2012-02-14 Albert Einstein College Of Medicine Of Yeshiva University Multi-microRNA methods and compositions
CA2690627C (en) * 2007-06-15 2014-12-02 Genelux Corporation Microorganisms for imaging and/or treatment of tumors
WO2008155397A2 (en) 2007-06-20 2008-12-24 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases
US8841437B2 (en) * 2008-06-20 2014-09-23 The Board Of Trustees Of The Leland Stanford Junior University Precursor miRNA loop-modulated target regulation
JP4517096B2 (en) * 2007-07-17 2010-08-04 愛知県 Cancer gene therapy vector and pharmaceutical composition for cancer therapy
WO2009036332A1 (en) 2007-09-14 2009-03-19 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
WO2009054996A2 (en) * 2007-10-25 2009-04-30 Genelux Corporation Systems and methods for viral therapy
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
WO2009151591A2 (en) * 2008-06-10 2009-12-17 Sangamo Biosciences, Inc. Methods and compositions for generation of bax- and bak-deficient cell lines
WO2010008562A2 (en) 2008-07-16 2010-01-21 Recombinetics Methods and materials for producing transgenic animals
EP2816113A3 (en) 2008-09-11 2015-03-25 Galapagos N.V. Method for identifying compounds useful for increasing the functional activity and cell surface expression of cf-associated mutant cystic fibrosis transmembrane conductance regulator
US20120004160A1 (en) 2009-02-19 2012-01-05 Glaxo Group Ltd. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
US20110306655A1 (en) 2009-02-19 2011-12-15 Richard Antonius Jozef Janssen Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
JP2012518181A (en) 2009-02-19 2012-08-09 ガラパゴス・ナムローゼ・フェンノートシャップ Identification method and compound useful for diagnosis and treatment of diseases including inflammation
WO2010112569A1 (en) 2009-03-31 2010-10-07 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
EP2414830A2 (en) 2009-03-31 2012-02-08 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
US8663930B2 (en) 2009-04-01 2014-03-04 Galapagos Nv Methods and means for treatment of osteoarthritis
WO2011015573A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011015572A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
TW201120043A (en) 2009-11-05 2011-06-16 Galapagos Nv Fused pyrazine compounds as their salts, useful for the treatment of degenerative and inflammatory diseases
CA2780875A1 (en) 2009-11-13 2011-05-19 Pangaea Biotech, S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US20130183326A9 (en) 2009-11-20 2013-07-18 St. Jude Children's Research Hospital Methods and compositions for modulating the activity of the interleukin-35 receptor complex
US20110196016A1 (en) * 2010-02-05 2011-08-11 Anke Geick Compositions and Methods for Inhibiting Expression of IKK2 Genes
JP5794558B2 (en) * 2010-03-24 2015-10-14 国立研究開発法人産業技術総合研究所 Modified lethal gene and vector containing the gene
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
US8993532B2 (en) 2010-04-23 2015-03-31 Cold Spring Harbor Laboratory Structurally designed shRNAs
EP3434772A3 (en) 2010-10-18 2019-03-20 Arrowhead Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of rrm2 genes
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
US20140157443A1 (en) 2011-04-14 2014-06-05 St. Jude Children's Research Hospital Methods and compositions for detecting and modulating a novel mtor complex
ES2733211T3 (en) 2011-04-15 2019-11-28 Genelux Corp Attenuated clonal strains of vaccinia virus and methods of use thereof
EA024762B9 (en) 2011-06-30 2017-04-28 Эрроухэд Рисерч Корпорейшн Compositions and methods for inhibiting gene expression of hepatitis b virus
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
ES2670590T3 (en) 2012-11-20 2018-05-31 Centro De Investigacíon Biomédica En Red De Enfermedades Neurodegenerativas Ciberned Upper corticospinal motor neurons, methods and compositions for differentiating neural stem cells by modulating CB1 cannabinoid receptor signaling and uses thereof
WO2014139883A1 (en) 2013-03-14 2014-09-18 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrotic diseases
EP2972381A2 (en) 2013-03-14 2016-01-20 Galapagos NV Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition
WO2014139884A2 (en) 2013-03-14 2014-09-18 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrosis
CN112301024A (en) 2013-03-15 2021-02-02 通用医疗公司 Improving the specificity of RNA-guided genome editing using RNA-guided FokI nuclease (RFN)
US11332719B2 (en) * 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
EP2813571A1 (en) 2013-06-13 2014-12-17 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Method for the treatment of lung cancer
EP3052464B1 (en) 2013-10-04 2020-04-15 Novartis AG 3'end caps for rna-interferring agents for use in rna interference
WO2015051366A2 (en) 2013-10-04 2015-04-09 Novartis Ag Novel formats for organic compounds for use in rna interference
HK1221912A1 (en) 2013-10-04 2017-06-16 Novartis Ag Organic compounds to treat hepatitis b virus
CA2935032C (en) * 2013-12-26 2024-01-23 The General Hospital Corporation Multiplex guide rnas
WO2015134528A1 (en) * 2014-03-04 2015-09-11 Donald Danforth Plant Science Center New generation of artificial micrornas
CN107206088A (en) 2014-12-05 2017-09-26 豪夫迈·罗氏有限公司 It is used for the method and composition for the treatment of cancer using the axle antagonists of PD 1 and HPK1 antagonists
AU2016306275A1 (en) 2015-08-07 2018-02-08 Arrowhead Pharmaceuticals, Inc. RNAi therapy for Hepatitis B virus infection
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
JOP20190015A1 (en) 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
CN109456995A (en) * 2018-11-08 2019-03-12 杜以军 Gene knockout plasmid, cell line and preparation method and application
JP2022541197A (en) 2019-07-16 2022-09-22 ユニヴェルシテ・コート・ダジュール Methods of assessing susceptibility or resistance of a subject to oncolytic viruses, recombinant viruses, their preparation and use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029097A1 (en) * 1995-03-21 1996-09-26 Research Corporation Technologies, Inc. Stem-loop and circular oligonucleotides
WO1999064582A2 (en) * 1998-06-12 1999-12-16 Introgene B.V. High-throughput screening of gene function using libraries for functional genomics applications
WO2000011154A1 (en) * 1998-08-20 2000-03-02 Cell Genesys, Inc. USE OF SUPPRESSOR tRNA'S TO REGULATE CYTOTOXICITY DURING THE PRODUCTION OF RECOMBINANT GENE PRODUCTS
WO2000049035A1 (en) * 1999-02-19 2000-08-24 The General Hospital Corporation Gene silencing
WO2000052188A1 (en) * 1999-03-03 2000-09-08 Oxford Biomedica (Uk) Limited Packaging cells for retroviral vectors
WO2003012082A2 (en) * 2001-07-26 2003-02-13 Axordia Limited Method for modulating stem cell differentiation using stem loop rna

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US6060456A (en) * 1993-11-16 2000-05-09 Genta Incorporated Chimeric oligonucleoside compounds
US6146886A (en) * 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CN1202246C (en) † 1998-04-08 2005-05-18 联邦科学和工业研究组织 Methods for means for obtaining modified phenotypes
US6326193B1 (en) * 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
ES2336887T5 (en) * 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediators of RNA interference specific to RNA sequences
US20020132788A1 (en) * 2000-11-06 2002-09-19 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
CA2429814C (en) * 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
US6399378B1 (en) * 2001-03-01 2002-06-04 Isis Pharmaceuticals, Inc. Antisense modulation of RECQL2 expression
US20030148519A1 (en) * 2001-11-14 2003-08-07 Engelke David R. Intracellular expression and delivery of siRNAs in mammalian cells
US20040053876A1 (en) * 2002-03-26 2004-03-18 The Regents Of The University Of Michigan siRNAs and uses therof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029097A1 (en) * 1995-03-21 1996-09-26 Research Corporation Technologies, Inc. Stem-loop and circular oligonucleotides
WO1999064582A2 (en) * 1998-06-12 1999-12-16 Introgene B.V. High-throughput screening of gene function using libraries for functional genomics applications
WO2000011154A1 (en) * 1998-08-20 2000-03-02 Cell Genesys, Inc. USE OF SUPPRESSOR tRNA'S TO REGULATE CYTOTOXICITY DURING THE PRODUCTION OF RECOMBINANT GENE PRODUCTS
WO2000049035A1 (en) * 1999-02-19 2000-08-24 The General Hospital Corporation Gene silencing
WO2000052188A1 (en) * 1999-03-03 2000-09-08 Oxford Biomedica (Uk) Limited Packaging cells for retroviral vectors
WO2003012082A2 (en) * 2001-07-26 2003-02-13 Axordia Limited Method for modulating stem cell differentiation using stem loop rna

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ELBASHIR SAYDA M ET AL: "RNA interference is mediated by 21- and 22-nucleotide RNAs.", GENES & DEVELOPMENT, vol. 15, no. 2, 15 January 2001 (2001-01-15), pages 188 - 200, XP002204651, ISSN: 0890-9369 *
HUTVAGNER GYORGY ET AL: "A cellular function for the RNA-interference enzyme dicer in the maturation of the let-7 small temporal RNA.", SCIENCE (WASHINGTON D C), vol. 293, no. 5531, 3 August 2001 (2001-08-03), pages 834 - 838, XP002204649, ISSN: 0036-8075 *
MEDINA M F C ET AL: "RNA POLYMERASE III-DRIVEN EXPRESSION CASSETTES IN HUMAN GENE THERAPY", CURRENT OPINION IN MOLECULAR THERAPEUTICS, vol. 1, no. 5, October 1999 (1999-10-01), pages 580 - 594, XP001055319, ISSN: 1464-8431 *
PADDISON PATRICK J ET AL: "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells.", GENES & DEVELOPMENT, vol. 16, no. 8, 15 April 2002 (2002-04-15), pages 948 - 958, XP002204653, ISSN: 0890-9369 *
PASQUINELLI AMY E ET AL: "Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA.", NATURE (LONDON), vol. 408, no. 6808, 2000, pages 86 - 89, XP002204652, ISSN: 0028-0836 *
RAYKOV Z ET AL: "Transient suppression of transgene expression by means of antisense oligonucleotides: A method for the production of toxin-transducing recombinant viruses.", GENE THERAPY, vol. 9, no. 5, March 2002 (2002-03-01), pages 358 - 362, XP002253225, ISSN: 0969-7128 *
YU JENN-YAH ET AL: "RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 99, no. 9, 30 April 2002 (2002-04-30), pages 6047 - 6052, XP002204654, ISSN: 0027-8424 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946177B2 (en) 2004-11-12 2015-02-03 Mima Therapeutics, Inc Methods and compositions involving miRNA and miRNA inhibitor molecules

Also Published As

Publication number Publication date
DE60225586T2 (en) 2009-04-02
EP1444346B2 (en) 2015-06-24
EP1444346B1 (en) 2008-03-12
JP2005501557A (en) 2005-01-20
WO2003020931A2 (en) 2003-03-13
ATE389016T2 (en) 2008-03-15
DE60225586T3 (en) 2015-12-03
AU2002339458A1 (en) 2003-03-18
DE60225586D1 (en) 2008-04-24
CA2457419A1 (en) 2003-03-13
US20050214851A1 (en) 2005-09-29
EP1444346A2 (en) 2004-08-11
US20030198627A1 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
WO2003020931A3 (en) Sirna knockout assay method and constructs
WO2005012487A3 (en) Compositions and methods for preparing short rna molecules and other nucleic acids
WO2003016482A3 (en) Methyltransferase genes and uses thereof
WO2001060974A3 (en) Method for an extraction of proteins from a single cell
WO2003097810A3 (en) Nitrilases, nucleic acids encoding them and methods for making and using them
WO2003034812A3 (en) Aromatic methyltransferases and uses thereof
WO2002012478A3 (en) Methyl-d-erythritol phosphate pathway genes
WO2006018836A3 (en) Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues
WO2005087951A3 (en) Reagents, methods and kits for use in deactivating nucleic acids
WO2001096373A3 (en) Fluorescent timer proteins and methods for their use
WO2000053776A3 (en) Human kallikrein-like genes
WO2003040681A3 (en) Genes coding for metabolic pathway proteins
WO2005054439A3 (en) Small interfering rna (sirna)-mediated heritable gene manipulation in plants
WO2004013333A3 (en) Inversion of the negative-selective effect of negative marker proteins using selection methods
WO2005018552A3 (en) Heparin binding proteins: sensors for heparin detection
WO2006045591A3 (en) Method and constructs for delivering double stranded rna to pest organisms
WO2009116984A3 (en) Highly thermostable fluorescent proteins
WO2003044168A3 (en) Facilitation of rna interference
WO2003031642A3 (en) lovE VARIANT REGULATOR MOLECULES
WO2004087883A3 (en) lovE VARIANT REGULATOR MOLECULES
AU2002258617A1 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
WO2001062911A3 (en) Antisense and catalytically acting nucleic acid molecules targeted to grb2- related with insert domain (grid) proteins and their uses
WO2006128084A3 (en) Trps1-mediated modulation of hair growth
WO2003040357A3 (en) Genes coding for phosphoenolpyruvate-sugar-phosphotransferase proteins
AU2002356494A1 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2457419

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003525634

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002776950

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002776950

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002776950

Country of ref document: EP